Clinical trial
Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant…
NCT00429559 · Hellenic Oncology Research Group, Other · Completed
Key facts
| NCT number | NCT00429559 |
|---|---|
| Title | Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma |
| Official title | Weekly Administration of Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer |
| Lead sponsor | Hellenic Oncology Research Group, Other |
| Collaborators | University Hospital of Crete |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | Hycamptin, Gemcitabine |
| Enrollment | 31 |
| Start date | Jun 1, 2006 |
| Primary completion | Jul 1, 2011 |
| Completion | Jul 1, 2011 |
| First posted | Jan 31, 2007 |
| Last update posted | Jul 22, 2011 |
| Countries | Greece |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: